Horsham, Pa. (April 18, 2016) – DIA recently announced that Jonathan Commons has been named senior vice president of marketing. He will lead the global marketing and business development teams for DIA.
Prior to joining DIA, Commons worked for more than a decade in the Pharmaceutical industry. He most recently served in global roles as the Senior Director of Digital and Patient Engagement at Chimerix and Vice President of Investigator Education and Patient Engagement at Quintiles. At GlaxoSmithKline (GSK) he worked on the commercialization of pharmaceutical products across a range of therapeutic areas including Oncology, Cardiovascular, Infectious Disease, Rare Disease, Acute Care and Pain, and was responsible for developing Patient and Healthcare Provider strategies and engaging consumer experiences.
DIA’s largest global interdisciplinary event, DIA 2016, will take place this summer in Philadelphia from June 26-30, 2016.
Commons earned his undergraduate degree in New Zealand at Massey University and his MBA at the University of North Carolina at Chapel Hill.
ABOUT DIA
For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global professionals a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.
DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, Africa and the Middle East (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and, Tokyo, Japan). For more information, visit our website at www.DIAglobal.org or contact us via Twitter @DrugInfoAssn, LinkedIn or on Facebook.
